StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Research analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

ADXS stock opened at $0.03 on Wednesday. The company has a fifty day moving average price of $0.05 and a 200 day moving average price of $0.10. Ayala Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $1.49. The company has a market cap of $1.15 million, a price-to-earnings ratio of 0.00 and a beta of 1.70.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.